Timolol can control IOP spikes after phaco

Article

Medically well-controlled glaucoma patients and patients with exfoliation syndrome may experience intraocular pressure (IOP) elevation shortly after cataract surgery. This can be controlled by the instillation of timolol maleate 0.5%.

Medically well-controlled glaucoma patients and patients with exfoliation syndrome may experience intraocular pressure (IOP) elevation shortly after cataract surgery. This can be controlled by the instillation of timolol maleate 0.5%, according to a report published in the January issue of Ophthalmology.

Hani Levkovitch-Verbin from the Goldschleger Eye Institute, Sheba Medical Center, Israel and colleagues from Tel-Aviv University, Israel conducted a prospective, randomized, double-masked clinical trial of 122 subjects with normal eyes, medically well-controlled glaucoma or exfoliation syndrome who had undergone uneventful phacoemulsification. Patients were randomly assigned to either an immediately postoperative drop of timolol maleate 0.5% or no treatment.

Changes in postoperative IOP differed significantly between glaucoma, exfoliation syndrome and normal eyes (r=0.005). IOP was significantly lower in the normal group (n=25) than in the glaucoma (n=18) and exfoliation syndrome (n=19) groups (r<0.001). Timolol significantly reduced postoperative IOPs over time in eyes with glaucoma but had no significant effect on either normal eyes or eyes with exfoliation syndrome.

Among eyes with glaucoma, 10 (55%) developed IOPs greater than 25 mmHg and five (28%) had IOPs greater than 30 mmHg. Among eyes with exfoliation syndrome, five (27%) had IOPs greater than 25 mmHg and two eyes (11%) had IOPs greater than 30 mmHg.

This research suggests that administering timolol immediately postoperatively can help prevent IOPs greater than 30 mmHg, although lower IOP elevations can still occur.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.